The successful treatment of mpox with brincidofovir in renal transplant recipients-a report of 2 cases

Int J Infect Dis. 2024 Jun:143:107015. doi: 10.1016/j.ijid.2024.107015. Epub 2024 Mar 21.

Abstract

An mpox outbreak was declared in July 2022 by the world health organization (WHO). It causes a mild self-limiting disease however; in immunosuppressed hosts, it tends to cause severe disseminated infection. Most cases of mpox in sold organ transplant (SOT) recipients reported in the literature were treated with tecovirimat. Here we report two cases of severe disseminated mpox infection in renal transplant recipients that were successfully treated with brincidofovir. Both patients were discharged from the hospital with no immediate significant side effects from brincidofovir reported until the submission of this report.

Keywords: Brincidofovir; Kidney transplant; Monkeypox virus; Mpox; Renal transplant; Solid organ transplant.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antiviral Agents* / therapeutic use
  • Cytosine* / analogs & derivatives*
  • Cytosine* / therapeutic use
  • Humans
  • Immunocompromised Host*
  • Kidney Transplantation* / adverse effects
  • Male
  • Middle Aged
  • Organophosphonates* / therapeutic use
  • Transplant Recipients
  • Treatment Outcome

Substances

  • Antiviral Agents
  • Cytosine
  • brincidofovir
  • Organophosphonates